Relevance of an Adapted and Supervised Physical Activity Program in Fibromyalgia Patients. The FIMOUV 1 Study.
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Nov 8, 2018
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient lived in t Loire (42) or Haute-Loire (43)
- • Patient diagnosed with fibromyalgia according to ACR (American College of rheumatology) criteria (total score WPI (Widespread Pain Index) + SS (Severity Scale) ) ≥ 13
- • French writing and speaking
- • Sedentary or low level of activity (less than 2 hours of regular physical activity per week at the time of inclusion)
- • Signature of informed consent
- Exclusion Criteria:
- • Cardiac or respiratory diseases that contraindicate the practice of physical activity
- • Significant co-morbidities that contraindicate the practice of physical activity: associated cardiac pathologies (severe rhythm disorders such as rapid atrial fibrillation), respiratory pathologies (severe obstructive or severe respiratory insufficiency), disabling joint pathologies (knee osteoarthritis or osteoarthritis of the hip) training on a treadmill or on a high intensity bike).
- • Impossibility of submitting to the medical monitoring of the program for geographical, social or psychological reason
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Etienne, , France
Patients applied
Trial Officials
David HUPIN, MD
Principal Investigator
CHU de Saint Etienne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials